Thursday's Health Winners & Losers

Stock quotes in this article: NOVN , CTIC , BIIB , BNT , ADPI  

In spite of positive regulatory and business news, health stocks held to the rest of the markets on Thursday leaving biotech indices a bit in the red.

Noven Pharmaceuticals(NOVN Quote) said Wednesday after the close that the U.S. Food and Drug Administration sent a tentative approval letter for the company's Stavzor. The drug is for manic episodes related to bipolar disorder and used as a therapy for multiple types of seizures, as well as a preventative for migraine headaches.

Tentative approval generally indicates the agency has concluded that a drug has met the required quality, safety and efficacy standards, but it cannot be marketed in the U.S. yet due to existing patents and/or exclusivity rights, according to the company. Noven expects the FDA's final approval by the end of July 2008. Shares rose a bit and then fell back 25 cents, or 1.72%, to $14.80 on Thursday.

On the business side, Cell Therapeutics Inc.(CTIC Quote) said Thursday that it completed the buyout of Biogen Idec's(BIIB Quote) Zevalin for non-Hodgkin's Lymphoma (NHL). The drug is approved for NHL patients who've tried another therapy unsuccessfully.

Per the deal announced in August, CTI made an upfront payment of $10 million in exchange for control of U.S. marketing, sales and development of Zevalin, and will pay an additional $20 million in milestone payments if Zevalin is approved as a first line, or initial, treatment for NHL. CTI will also pay sales royalties for Zevalin until at least December 2015, according to the companies.

  • Loading Comments...
  •  
< Previous
1 2

SHARE:

  • email
  • print
  • comment
  • digg
  • delicious
  • linkedin




Connect with TheStreet

Dow Jones S&P 500 NASDAQ 10-Year Note
10,270.47 1,093.48 2,167.88 34.29
Oil *
75.55
UP
73.00
UP
6.24
UP
18.86
DOWN
0.17
10 Yr
3.43%
SPDR Gold
109.74
+0.72%
+0.57%
+0.88%
-0.49%
Data delayed 20 minutes

Brokerage Partners

TheStreet Premium Services

All Services